| アブストラクト | INTRODUCTION: Drug-induced hypertension was described with several pharmacological classes. The association between hypertension and antidepressant drugs (AD) is controversial. The objective of this study was to evaluate the link between hypertension and ADs. MATERIALS AND METHODS: A retrospective disproportionality analysis from observations consecutively reported to the French pharmacovigilance database between 1985 and 2020 was performed. The relationship between the suspected ADs and the occurrence of hypertension was assessed by calculating the reporting odds ratio (ROR) in a case/non-case design. A negative (paracetamol) and a positive (celecoxib) control were used to validated this disproportionality method. RESULTS: We compared 6725 cases (including 464 AD-related cases) to 789,483 non-cases (including 56,440 AD-related cases). The reporting of hypertension was significantly associated with serotonin/norepinephrine reuptake inhibitors (SNRI) (ROR 1.43, 95 % CI 1.26-1.64) and monoamine oxidase inhibitors (MAOI) (ROR 6.41, 95 % CI 4.25-9.67) but not with other ADs classes. Concerning ADs analyzed independently of their AD class, a significant signal was observed with many SNRIs (duloxetin, milnacipran and venlafaxin) and with all MAOIs (moclobemide, iproniazide) (ROR between 2.04 and 17.93) but not with others ADs. The ROR value of positive (celecoxib) and negative (paracetamol) controls were ROR=1.53; IC95 %=1.04-2.26 and ROR=0.72; IC95 %=0.65-0.80, respectively. CONCLUSION: We found a significant association between development or worsening of hypertension and SNRIs and MAOIs but not with others ADs, in this study performed in real conditions of life. It is therefore advisable to remain cautious when prescribing ADs and to check systematically for hypertension. |
|---|
| ジャーナル名 | L'Encephale |
|---|
| 投稿日 | 2021/7/28 |
|---|
| 投稿者 | Hofferer, A; Dolladille, C; Chretien, B; Sassier, M; Laugier, D; Atzenhoffer, M; Bagheri, H; Alexandre, J; Fedrizzi, S; Humbert, X |
|---|
| 組織名 | Departement de medecine generale, UFR Sante, Normandie Universite, 2, rue des;Rochambelles, 14032 Caen cedex 5, France.;Centre regional de pharmacovigilance Caen Normandie, Caen, France; Service de;pharmacologie clinique, CHU Caen Normandie, Caen, France.;Centre regional de pharmacovigilance de Marseille, Marseille, France.;Centre regional de pharmacovigilance de Rhone-Alpes, Lyon, France.;Centre regional de pharmacovigilance de Midi Pyreneens, Toulouse, France.;Rochambelles, 14032 Caen cedex 5, France. Electronic address:;xavier.humbert@unicaen.fr. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34311965/ |
|---|
